The Liver Meeting 2023 – updates to the current landscape

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.